Harnessing the power of antibodies to fight bone metastasis
Open Access
- 25 June 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (26) , eabf2051
Abstract
Precision modification of antibodies with bone-targeting moieties unleashes their potential for the treatment of bone metastases.Keywords
All Related Versions
Funding Information
- National Institutes of Health (GM133706)
- National Institutes of Health (CA255894)
- National Institutes of Health (CA183878)
- National Institutes of Health (CA221946)
- U.S. Department of War (W81XWH-16-1-0073)
- U.S. Department of War (BC201371)
- U.S. Department of War (DAMD W81XWH-16-1-0073)
- Welch Foundation (C-1970)
- Cancer Prevention and Research Institute of Texas (RR170014)
- John S. Dunn Foundation Collaborative Research
- Hamill Innovation Award
- National Cancer Institute (CA183878)
- National Cancer Institute (CA221946)
This publication has 49 references indexed in Scilit:
- Antibody therapy of cancerNature Reviews Cancer, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- The relationship between the chemistry and biological activity of the bisphosphonatesBone, 2011
- Metastatic Behavior of Breast Cancer SubtypesJournal of Clinical Oncology, 2010
- The safety and side effects of monoclonal antibodiesNature Reviews Drug Discovery, 2010
- Molecular Biology of Bone MetastasisMolecular Cancer Therapeutics, 2007
- Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell PhenotypeClinical Cancer Research, 2006
- Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 2006
- Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patientsBreast Cancer Research and Treatment, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005